Cerenis Therapeutics Holding SA

ABIONYX Pharma

The company develops recombinant HDL-based biotherapies for patients with sepsis, renal diseases, and ophthalmological conditions.

Cereno Scientific

This biotech company develops epigenetic therapies for patients with rare cardiovascular and pulmonary diseases.

Staten Biotechnology

This company develops monoclonal antibody therapies for patients with dyslipidaemia to reduce cardiovascular risk and lower triglyceride levels.

CINC

This company develops biopharmaceutical treatments for cardio-renal diseases, primarily for patients with hypertension and chronic kidney disease.

Resalis Therapeutics

This company develops non-coding RNA therapies to treat metabolic disorders, including obesity and fatty liver disease, for patients with unmet medical needs.

Omthera Pharmaceuticals

This biopharmaceutical company develops omega-3 fatty acid therapies to treat patients with dyslipidemia and high triglyceride levels.

Corvidia Therapeutics

This clinical-stage biotechnology company develops precision therapies for patients with chronic kidney disease who are at high risk of cardiovascular events.

Mineralys Therapeutics

The company develops an aldosterone synthase inhibitor medicine to treat patients with uncontrolled or treatment-resistant hypertension and chronic kidney disease.